You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthyl carbamate
Accession NumberDB04827
TypeSmall Molecule
GroupsWithdrawn
DescriptionEthyl carbamate (also known as urethan and urethane), formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Structure
Thumb
Synonyms
Aethylcarbamat
Aethylurethan
Carbamic acid ethyl ester
Carbamidsaeure-aethylester
Estane 5703
Ethyl ester of carbamic acid
Ethyl urethan
Ethyl urethane
Ethylcarbamate
Ethylester kyseliny karbaminove
Ethylurethan
Ethylurethane
O-ethyl urethane
O-ethylurethane
Uretan
Uretan etylowy
Uretano
Urethan
Urethane
Urethanum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LeucethaneNot Available
LeucothaneNot Available
PracarbaminNot Available
PracarbamineNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3IN71E75Z5
CAS number51-79-6
WeightAverage: 89.0932
Monoisotopic: 89.047678473
Chemical FormulaC3H7NO2
InChI KeyInChIKey=JOYRKODLDBILNP-UHFFFAOYSA-N
InChI
InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
IUPAC Name
ethyl carbamate
SMILES
CCOC(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organooxygen compounds. These are organic compounds containing a bond between a carbon atom and an oxygen atom.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassNot Available
Sub ClassNot Available
Direct ParentOrganooxygen compounds
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9922
Caco-2 permeable+0.516
P-glycoprotein substrateNon-substrate0.892
P-glycoprotein inhibitor INon-inhibitor0.9593
P-glycoprotein inhibitor IINon-inhibitor0.9677
Renal organic cation transporterNon-inhibitor0.9397
CYP450 2C9 substrateNon-substrate0.8579
CYP450 2D6 substrateNon-substrate0.7888
CYP450 3A4 substrateNon-substrate0.7321
CYP450 1A2 substrateNon-inhibitor0.5553
CYP450 2C9 inhibitorNon-inhibitor0.9306
CYP450 2D6 inhibitorNon-inhibitor0.9168
CYP450 2C19 inhibitorNon-inhibitor0.9537
CYP450 3A4 inhibitorNon-inhibitor0.9765
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9452
Ames testAMES toxic0.7773
CarcinogenicityNon-carcinogens0.6285
BiodegradationReady biodegradable0.6313
Rat acute toxicity1.6607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9864
hERG inhibition (predictor II)Non-inhibitor0.9783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point49 °CPhysProp
boiling point185 °CPhysProp
water solubility4.8E+005 mg/L (at 15 °C)SEIDELL,A (1941)
logP-0.15HANSCH,C ET AL. (1995)
logS0.85ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility371.0 mg/mLALOGPS
logP-0.14ALOGPS
logP-0.054ChemAxon
logS0.62ALOGPS
pKa (Strongest Acidic)15.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity20.84 m3·mol-1ChemAxon
Polarizability8.64 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.45 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-01r7-9000000000-dbaaf921e6f73cb42292View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Norton A. Cashen, “Method of producing anhydrous crystalline reaction products of formaldehyde and methyl-, ethyl carbamate.” U.S. Patent US4002668, issued July, 1973.

US4002668
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl carbamate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.
adipiplonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl carbamate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethyl carbamate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate.
AmisulprideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate.
AmoxapineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.
ArticaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azaperone.
AzelastineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethyl carbamate.
BaclofenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl carbamate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benzyl alcohol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Ethyl carbamate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
BrimonidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate.
BrompheniramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethyl carbamate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate.
ButacaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethyl carbamate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethyl carbamate.
CarisoprodolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl carbamate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethyl carbamate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate.
CitalopramThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl carbamate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate.
CyclizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.
CyproheptadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.
DapoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate.
DesipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ethyl carbamate.
DesloratadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl carbamate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethyl carbamate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl carbamate.
DifenoxinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Difenoxin.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.
DigoxinDigoxin may decrease the cardiotoxic activities of Ethyl carbamate.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.
DoramectinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
DoxylamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethyl carbamate.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethyl carbamate.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethyl carbamate.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethyl carbamate.
EfavirenzThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethyl carbamate.
EntacaponeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl carbamate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate.
EthanolEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethyl carbamate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.
EthosuximideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethotoin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl carbamate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate.
EtidocaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.
EtoperidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate.
EzogabineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate.
FenfluramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate.
FexofenadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate.
FlunarizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl carbamate.
FluoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate.
FluspirileneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethyl carbamate.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethyl carbamate.
GuanfacineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethyl carbamate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethyl carbamate.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethyl carbamate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
HydroxyzineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethyl carbamate.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethyl carbamate.
LevocabastineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.
LofentanilThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl carbamate.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate.
Lu AA21004The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethyl carbamate.
MelperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.
MetaxaloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethyl carbamate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate.
MethaqualoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethyl carbamate.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate.
MethsuximideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate.
MetyrosineEthyl carbamate may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.
MilnacipranThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
MirtazapineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethyl carbamate.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.
NabiloneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate.
OpiumThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Opium.
OrphenadrineEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethyl carbamate.
OsanetantThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.
OuabainOuabain may decrease the cardiotoxic activities of Ethyl carbamate.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl carbamate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.
ParaldehydeEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ethyl carbamate.
ParoxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate.
PerampanelThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate.
PipamperoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.
PramipexoleEthyl carbamate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl carbamate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethyl carbamate.
PrimidoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl carbamate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.
PromethazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.
PropoxycaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.
RamelteonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.
RomifidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Romifidine.
RopiniroleEthyl carbamate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate.
RotigotineEthyl carbamate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl carbamate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethyl carbamate.
ScopolamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.
SertindoleThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.
SuvorexantThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate.
TetrabenazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrodotoxin.
ThalidomideEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethyl carbamate.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.
TiagabineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl carbamate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ethyl carbamate.
TrazodoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.
TrimipramineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethyl carbamate.
VigabatrinThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate.
ZiconotideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.
ZolazepamThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethyl carbamate.
ZonisamideThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethyl carbamate.
ZotepineThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Dinnes DL, Santerre JP, Labow RS: Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9. [PubMed:15626436 ]
  2. Labow RS, Santerre JP, Waghray G: The effect of phospholipids on the biodegradation of polyurethanes by lysosomal enzymes. J Biomater Sci Polym Ed. 1997;8(10):779-95. [PubMed:9297603 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Kotanidou A, Choi AM, Winchurch RA, Otterbein L, Fessler HE: Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-alpha release. J Appl Physiol (1985). 1996 Nov;81(5):2305-11. [PubMed:8941558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Sugihara K, Kitamura S, Tatsumi K: Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. J Pharmacobiodyn. 1983 Sep;6(9):677-83. [PubMed:6689178 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:32 / Updated on August 17, 2016 12:24